Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities hit a record high in the ...

Wondering whether Madrigal Pharmaceuticals might be undervalued or perhaps riding a little too high? You are not alone, as many investors are digging into its numbers to decide if there is real value ...

Madrigal’s drug Rezdiffra has exceeded expectations, and the company plans to stay ahead of incoming competition with a ...

Madrigal Pharmaceuticals is aiming to accomplish what has so far proven to be impossible: to bring a fatty liver drug across the FDA finish line and onto the market. That hope, which could be worth ...

Madrigal Pharmaceuticals, Inc. has secured a $500 million senior secured credit facility from Blue Owl Capital to advance its pipeline focused on treating metabolic dysfunction-associated ...

CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Fresh analyst target hikes followed new two-year clinical data showing sustained improvements in key liver-health measures.